| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | 0.2 | 0.008 |
| mRNA | TGX221 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.009 |
| mRNA | COL-3 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.01 |
| mRNA | Bleomycin | GDSC1000 | pan-cancer | AAC | -0.09 | 0.01 |
| mRNA | FH535 | GDSC1000 | pan-cancer | AAC | -0.086 | 0.01 |
| mRNA | Vorinostat | gCSI | pan-cancer | AAC | 0.13 | 0.01 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | 0.091 | 0.02 |
| mRNA | Vorinostat | GDSC1000 | pan-cancer | AAC | 0.075 | 0.02 |
| mRNA | BRD-K27986637 | CTRPv2 | pan-cancer | AAC | 0.17 | 0.02 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.083 | 0.02 |